Thymalin
Thymulin, Thymic Factor, Serum Thymic Factor, Facteur Thymique Serique
Completed
NA
INTERVENTIONAL
NCT05397535
Baduanjin Lower Elevated Blood PreSsure Study
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The aim of this study is to evaluate the effects of Baduanjin on blood pressure in individuals with high normal blood pressure (SBP 130-139 mmHg, and/or DBP 85-89 mmHg), as well as on glucose and lipid metabolism, quality of life, psychology, exercise, immune inflammation, endothelial function, and arterial stiffness.
Interventions
Name:
Baduanjin
Type:
BEHAVIORAL
Description:
Participants in Baduanjin group will receive health education on hypertension and attend a 4-hour class to learn Baduanjin before receiving the interventions after the randomization. Baduanjin exercise protocol is based on the "Fitness Qigong Baduanjin Standard" enacted by the General Administration of Sports in 2003. Each Badaunjin exercise session will last at least 30 minutes and be conducted at least 5 days per week for 52 weeks. These participants will be required to practice Baduanjin regularly, and the researchers will monitor their adherence to practice and provide reminders if needed.
Name:
Brisk walking
Type:
BEHAVIORAL
Description:
Participants in this group will receive health education on hypertension and practice brisk walking on their own for at least 30 minutes, at least 5 days per week for 52 weeks. These participants will be required to do brisk walking regularly, and the researcher will monitor their adherence to practice and provide reminders if needed.
Primary Outcomes
Measure:
Change from baseline ambulatory 24-h systolic blood pressure (mmHg) at 12 week
TimeFrame:
Baseline, 12 week
Description:
Change form Baseline ambulatory 24-h systolic blood pressure at 12 week will be measured by ambulatory blood pressure monitoring to investigate the short-term antihypertensive effect of Baduanjin.
Measure:
Change from baseline ambulatory 24-h systolic blood pressure (mmHg) at 52 week
TimeFrame:
Baseline, 52 week
Description:
Change from baseline ambulatory 24-h systolic blood pressure at 52 week will be measured by ambulatory blood pressure monitoring to investigate the long-term antihypertensive effect of Baduanjin.
Trial Information
NCT ID
NCT05397535
Status
Completed
Study Type
INTERVENTIONAL
Phases
NA
Sponsor
China National Center for Cardiovascular Diseases
Last Updated
December 15, 2025